Medical team seeks advances beyond mainstream stem cell
technology to cure degenerative diseases and injuries
OXNARD, Calif., January 10, 2010—Regenerative medicine start-up Celavie Biosciences LLC has appointed three prestigious medical innovators to its advisory team. The company’s R&D focuses on using regenerative stem cell therapies to repair tissues that have been damaged by disorders of the central nervous system by use, trauma, or chronic disease, such as Parkinson’s and Huntington’s diseases, which have no long-term treatments or cures.
Innovation advances applications of stem cells in regenerative medicine sector
OXNARD, Calif., Dec. 15, 2009—The U.S. Patent and Trademark Office issued a patent to regenerative medicine company Celavie Biosciences LLC for novel propagation and transplantation methods of pluripotent stem cells (PSC) and neural progenitor cells (NPC) with applications for therapeutic, diagnostic, and research purposes in the treatment of degenerative diseases.
Regenerative medicine start-up demonstrates efficacy and safety
OXNARD, Calif., August 19, 2008—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, conducted a successful pilot study of Celavet’s OK100 stem cells to investigate safety, efficacy, and prospective methodology for use of undifferentiated stem cells in the repair of equine connective soft tissue injuries.
New stem cell technology tested as innovative treatment for equine injuries
OXNARD, Calif., April 14, 2008—Regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, has added a robust team of veterinary experts to advance research on a new stem cell technology designed to provide alternative approaches to therapy in orthopedic conditions for large and small animals. Celavet’s team of specialists is focused on restoring health and mobility to animals suffering from musculoskeletal injuries, torn ligaments and tendons, osteoarthritis, burns, and other injuries, with an initial focus on equine applications.
Initial R&D focuses on enabling injured horses to regain
fullest potential as competitors, performers, workers or companions
OXNARD, Calif., March 20, 2008—Celavie Biosciences LLC has expanded their research on stem cell treatment to veterinary applications with a new subsidiary, Celavet Inc. Targeting the veterinary marketplace, the regenerative medicine company develops stem cell-based therapies for the treatment and prevention of orthopedic injuries and diseases in large and small animals, restoring health and mobility.
Kopyov will play instrumental role in R&D of stem cell technology for neurodegenerative disease applications
OXNARD, Calif., November 28, 2006—Celavie Biosciences LLC named Oleg Kopyov, MD, PhD Chief Scientific Officer and Executive Vice President to lead a team working to advance regenerative medicine beyond mainstream stem cell technology. Dr. Kopyov has been researching treatments and technologies now under development at Celavie for over 25 years. He has served as Director of Research for the California Neuroscience Institute at St. John’s Regional Medical Center in Los Angeles.
Regenerative medicine company develops therapies for
Parkinson’s disease and other central nervous system disorders
OXNARD, Calif., April 30, 2006—Advancement in medical treatments for degenerative diseases has a new ally in Celavie Biosciences LLC, newly founded and funded by entrepreneur Sandy Solmon, CEO of Sweet Street Desserts®. The private, emerging-growth medical technology company develops stem cell-based regenerative therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS), for which there are no long-term treatments or cures.
